|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PyMT (polyomavirus middle T-antigen) and human MUC1 double-transgenic mice expressing human tumor-associated MUC1 on breast tumor tissue served as a preclinical breast cancer model.
|
30413430 |
2019 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This antibody targets exclusively tumor-associated MUC1 in the absence of any binding to MUC1 on healthy epithelial cells thus enabling the generation of breast tumor-specific radiolabeled immune therapeutic tools.
|
31588183 |
2019 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A tumor microarray of 94 estrogen receptor-positive human breast tumors correlated coexpression of MUC1 and IFITM1 with poor recurrence-free survival, poor overall survival, and AI-resistance.
|
30655323 |
2019 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These treatment regimens were explored for the treatment of orthotopic MUC1-expressing breast tumors in mice transgenic for human MUC1.
|
31693710 |
2019 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The specific CDK4/6 inhibitor PD0332991 (palbociclib) was recently approved by the FDA and EMA for treatment of advanced ER-positive breast tumors.
|
28566333 |
2017 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Analysis of microarray databases further showed that (i) Rab31 is expressed at higher levels in breast cancers as compared to that in normal breast tissues, (ii) MUC1+ and ER+ breast cancers have increased levels of Rab31 expression, and (iii) patients with Rab31-positive breast tumors have a significantly decreased ten-year overall survival as compared to those with Rab31-negative tumors.
|
22792175 |
2012 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
AS1402 is a humanized immunoglobulin G1 antibody that targets the aberrantly glycosylated antigen MUC1, which is overexpressed in 90% of breast tumors and contributes to estrogen-mediated growth and survival of breast cancer cells in vitro by modulating estrogen receptor (ER) activity.
|
21878535 |
2011 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The first aim of this project was to study new possibilities for distinguishing benign from malignant tumors using growth factors and to compare them with the traditional tumor markers Carcinoembryonic antigen (CEA) and Cancer antigen 15-3 (CA15-3) for breast tumors.
|
22199345 |
2011 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because blocking MUC1 CD with an inhibitory peptide (PMIP) inhibited breast tumor growth, we tested whether PMIP would inhibit lung adenocarcinoma cell proliferation.
|
21862684 |
2011 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The growth of MUC1-positive breast tumors from hu-PBL-SCID mice immunized with two vaccines was significantly inhibited.
|
20127358 |
2010 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These findings indicate that (i) MUC1 and STAT1 function in an auto-inductive loop, and (ii) activation of both MUC1 and the STAT1 pathway in breast tumors confers a poor prognosis for patients.
|
19915608 |
2010 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Selected variants of 12ESC-6 demonstrated improved staining of MUC1 on cell lines using flow cytometry and improved staining of the antigen in breast tumor tissue by immunohistochemistry.
|
19776674 |
2009 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Collectively, we showed that the amplified mucin-1 promoter-driven vector is able to deliver to and selectively express a desirable transgene in metastatic lesions of breast tumors.
|
19366829 |
2009 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The MUC1 568 A/G polymorphism strongly influences CA 15-3 levels in healthy women and women with either benign or malignant breast tumors.
|
19121298 |
2009 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A significant correlation between the presence of MUC1-positive cells and the group of breast tumors was observed.
|
10955792 |
2000 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Coimmunoprecipitation analyses clearly revealed the presence of complexes composed of MUC1/Y and its cognate binding proteins in primary breast tumor tissue.
|
10197628 |
1999 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A gene dosage effect is responsible for high overexpression of the MUC1 gene observed in human breast tumors.
|
9309122 |
1997 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Muc1-H23 is a cell surface mucin that is expressed on normal breast luminal epithelial cells and over-expressed in most breast tumors.
|
9154467 |
1997 |
|
Mammary Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the growth rate of primary breast tumors induced by polyoma middle T antigen was found to be significantly slower in Muc-1 deficient mice.
|
8530414 |
1995 |
|
Mammary Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The authors examined several loci (ERBB2, INT2, MUC1) for gene amplification or loss of heterozygosity by Southern blotting and for gene expression by immunohistochemistry in breast tumors from patient groups selected by survival.
|
1355402 |
1992 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The PEM probe has been mapped to the chromosome band 1q21, a region that is often incriminated in chromosomal rearrangements in breast tumours.
|
2307533 |
1990 |
|
Mammary Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The breast tumour-associated epithelial mucins and the peanut lectin binding urinary mucins are coded by a single highly polymorphic gene locus 'PUM'.
|
3168399 |
1988 |